Condition: Malaria (Plasmodium Falciparum) · Sponsor: Victoria Biomedical Research Institute
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
This description comes directly from the study's public registry record.
Dr. Quentin Awori, MBChB · +254722913616 · qawori@vibriafrica.org
David Owino Ogolla, Msc · +254714421248 · dogolla@vibriafrica.org
Always discuss trial participation with your own doctor first.
| Victoria Biomedical Research Institute | Kisumu, Kenya | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07559370